Bioenvision (BIVN) Reports a Q4 Loss
Bioenvision, Inc. (Nasdaq: BIVN) reports a Q4 loss of $0.17 vs. consensus for $0.15 loss. Revenues were $6.75 million vs. $5.67 million consensus.
(The 2007 fourth quarter net loss included a one-time non-cash impairment loss equal to the carrying value of Suvus® as an intangible asset of approximately $3,311,000)
(The 2007 fourth quarter net loss included a one-time non-cash impairment loss equal to the carrying value of Suvus® as an intangible asset of approximately $3,311,000)
You May Also Be Interested In
- UPDATE: Bristow Group (BRS) Reports Better-Than-Expected Q4 Results; Offers FY13 Outlook
- Toro Co. (TTC) Tops Q1 EPS by 13c; Guides FY12 EPS Above Views; to Split Stock
- Patterson Companies, Inc. (PDCO) Tops Q4 EPS by 5c; Guides FY12
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
